Details
Stereochemistry | ACHIRAL |
Molecular Formula | C14H21N5O2S |
Molecular Weight | 323.414 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCS(=O)(=O)N[C@H]1C[C@H](C1)N(C)C2=NC=NC3=C2C=CN3
InChI
InChIKey=IUEWXNHSKRWHDY-PHIMTYICSA-N
InChI=1S/C14H21N5O2S/c1-3-6-22(20,21)18-10-7-11(8-10)19(2)14-12-4-5-15-13(12)16-9-17-14/h4-5,9-11,18H,3,6-8H2,1-2H3,(H,15,16,17)/t10-,11+
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/27774822Curator's Comment: The description was created based on several sources, including
https://clinicaltrials.gov/ct2/show/NCT02201524 | https://www.google.com/patents/WO2014128591A1 | https://clinicaltrials.gov/ct2/show/NCT02780167
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27774822
Curator's Comment: The description was created based on several sources, including
https://clinicaltrials.gov/ct2/show/NCT02201524 | https://www.google.com/patents/WO2014128591A1 | https://clinicaltrials.gov/ct2/show/NCT02780167
PF-04965842 is an orally administered selective Janus kinase 1 (JAK1) inhibitor. PF-04965842 is currently in clinical trials for the treatment of autoimmune diseases.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2835 Sources: https://clinicaltrials.gov/ct2/show/NCT01835197 |
29.0 nM [IC50] | ||
Target ID: CHEMBL2971 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27774822 |
803.0 nM [IC50] | ||
Target ID: CHEMBL3553 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27774822 |
1259.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3334 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29672897 |
400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
PF-04965842 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
3712 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29672897 |
800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered: |
PF-04965842 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
18230 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29672897 |
400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
PF-04965842 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
23740 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29672897 |
800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered: |
PF-04965842 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.85 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29672897 |
400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
PF-04965842 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
4.88 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29672897 |
800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered: |
PF-04965842 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02201524
200 mg daily, 400 mg daily and 200 mg twice daily for 4 weeks
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.google.com/patents/WO2014128591A1
Canine whole blood was collected in sodium heparin tubes from 29 beagle dogs and 23 mixed breed dogs. Whole blood (20 μL) was plated in 96-well plates (Costar 3598) with 180 μL of medium (RPMI 1640, Gibco #21870-076, with 1% heat inactivated fetal bovine serum, Gibco #10082-39, 292 μg/ml L-glutamine, Gibco #250030-081, 100 u/ml penicillin and 100μg streptomycin per ml, Gi bco #15 140- 122) containing vehicle control or test compound (0.001 to 10 μΜ), concanavalin A (ConA; 1 μg/ml, Sigma C5275), and canine inter-leukin-2 (IL-2 ; 50 ng/ml , R&D Systems 1815-CL/CF). Wells containing whole blood, medium with vehicle control and no ConA or I L-2 were used as background controls. Plates were incubated at 37° C for 48 hours. Tritiated thymidine, 0.4 μα/well (Perkin Elmer, Net027A-005 MC), was added for 20 additional hours. Plates were frozen and then thawed, washed and filtered using a Brandel MLR-96 cell harvester and pre-wet filter mats (Wallac 1205-401, Perkin Elmer). Filters were d ried at 60° C for one hour (Precision 16EG convection oven) and placed into filter sample bags (Wallac 1205-411, Perkin Elmer) with 10 mL of scintillant (Wallac 1205-440, Perkin Elmer). Sealed filters were counted on a LKB Wallac 1205 Betaplate liquid scintillation counter.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL3544929
Created by
admin on Sat Dec 16 08:58:59 GMT 2023 , Edited by admin on Sat Dec 16 08:58:59 GMT 2023
|
PRIMARY | |||
|
78323835
Created by
admin on Sat Dec 16 08:58:59 GMT 2023 , Edited by admin on Sat Dec 16 08:58:59 GMT 2023
|
PRIMARY | |||
|
1622902-68-4
Created by
admin on Sat Dec 16 08:58:59 GMT 2023 , Edited by admin on Sat Dec 16 08:58:59 GMT 2023
|
PRIMARY | |||
|
300000002660
Created by
admin on Sat Dec 16 08:58:59 GMT 2023 , Edited by admin on Sat Dec 16 08:58:59 GMT 2023
|
PRIMARY | |||
|
2591476
Created by
admin on Sat Dec 16 08:58:59 GMT 2023 , Edited by admin on Sat Dec 16 08:58:59 GMT 2023
|
PRIMARY | |||
|
DTXSID301126581
Created by
admin on Sat Dec 16 08:58:59 GMT 2023 , Edited by admin on Sat Dec 16 08:58:59 GMT 2023
|
PRIMARY | |||
|
C166985
Created by
admin on Sat Dec 16 08:58:59 GMT 2023 , Edited by admin on Sat Dec 16 08:58:59 GMT 2023
|
PRIMARY | |||
|
73SM5SF3OR
Created by
admin on Sat Dec 16 08:58:59 GMT 2023 , Edited by admin on Sat Dec 16 08:58:59 GMT 2023
|
PRIMARY | |||
|
FG-31
Created by
admin on Sat Dec 16 08:58:59 GMT 2023 , Edited by admin on Sat Dec 16 08:58:59 GMT 2023
|
PRIMARY | |||
|
DB14973
Created by
admin on Sat Dec 16 08:58:59 GMT 2023 , Edited by admin on Sat Dec 16 08:58:59 GMT 2023
|
PRIMARY | |||
|
Abrocitinib
Created by
admin on Sat Dec 16 08:58:59 GMT 2023 , Edited by admin on Sat Dec 16 08:58:59 GMT 2023
|
PRIMARY | |||
|
73SM5SF3OR
Created by
admin on Sat Dec 16 08:58:59 GMT 2023 , Edited by admin on Sat Dec 16 08:58:59 GMT 2023
|
PRIMARY | |||
|
11012
Created by
admin on Sat Dec 16 08:58:59 GMT 2023 , Edited by admin on Sat Dec 16 08:58:59 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE ACTIVE (PARENT)
METABOLITE ACTIVE (PARENT)
METABOLITE ACTIVE (PARENT)
METABOLITE ACTIVE (PARENT)